LIPUM Share Price Performance
SEK 14.20
1.20 (9.23%)
Price SEK 14.20
Share PriceSEK 14.20
LIPUM Community Narratives
There are no narratives available yet.
Recent LIPUM News & Updates
No updates
Lipum AB (publ) Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 28, 2025
- Earnings per share (EPS)
- -3.07
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 732.4%
Lipum AB (publ) Competitors
About LIPUM
- Founded
- 2010
- Employees
- 5
- CEO
- WebsiteView website
Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden.
Swedish Market Performance
- 7 Days: 0.6%
- 3 Months: 3.8%
- 1 Year: 2.5%
- Year to Date: 0.7%
In the last week, the market has stayed flat, however the Materials sector stood out, gaining 3.1%. Similarly, the market is flat for the past 12 months. As for the next few years, earnings are expected to grow by 17% per annum. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading